C
1.13
0.00 (0.00%)
| Previous Close | 1.13 |
| Open | 1.12 |
| Volume | 161,354 |
| Avg. Volume (3M) | 373,603 |
| Market Cap | 95,821,568 |
| Price / Book | 2.85 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -0.380 |
| Total Debt/Equity (MRQ) | 10.66% |
| Current Ratio (MRQ) | 0.360 |
| Levered Free Cash Flow (TTM) | -1.26 M |
| Return on Assets (TTM) | -22.41% |
| Return on Equity (TTM) | -93.64% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bullish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Mixed | |
| Stock | Citius Oncology, Inc. | Bullish | - |
AIStockmoo Score
-0.5
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -2.5 |
| Average | -0.50 |
|
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| % Held by Insiders | 86.80% |
| % Held by Institutions | 0.60% |
| 52 Weeks Range | ||
| Median | 6.00 (430.97%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Maxim Group | 23 Sep 2025 | 6.00 (430.97%) | Buy | 1.81 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |